Blinatumomab for treatment of children with high-risk relapsed B-cell acute lymphoblastic leukemia Editorial

  

Authors:	Shukla, N.; Sulis, M. L.
Title:	Blinatumomab for treatment of children with high-risk relapsed B-cell acute lymphoblastic leukemia
Keywords:	adolescent; cancer chemotherapy; cancer survival; child; event free survival; treatment outcome; disease-free survival; survival rate; young adult; review; cancer recurrence; cancer risk; drug safety; disease free survival; cytarabine; progression free survival; multiple cycle treatment; etoposide; incidence; recurrence; acute lymphoblastic leukemia; cancer survivor; b lymphocyte; b-lymphocytes; cancer regression; mitoxantrone; recurrent disease; precursor cell lymphoblastic leukemia-lymphoma; idarubicin; high risk population; health care delivery; inotuzumab ozogamicin; antibodies, bispecific; bispecific antibody; blinatumomab; humans; human; priority journal
Journal Title:	JAMA - Journal of the American Medical Association
Volume:	325
Issue:	9
ISSN:	0098-7484
Publisher:	American Medical Association
Date Published:	2021-03-02
Start Page:	830
End Page:	832
Language:	English
DOI:	10.1001/jama.2021.1395
PUBMED:	33651075
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102034607&doi=10.1001%2fjama.2021.1395&partnerID=40&md5=d62e46bfc18bb457bb7e794d1ea6f050
Notes:	Review -- Export Date: 1 April 2021 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/178280